| Literature DB >> 32387542 |
Joyce Kabagenyi1, Agnes Natukunda1, Jacent Nassuuna1, Richard E Sanya2, Margaret Nampijja1, Emily L Webb3, Alison M Elliott4, Gyaviira Nkurunungi5.
Abstract
Several vaccines elicit lower efficacy or impaired immune responses in rural compared to urban settings, and in tropical low-income countries compared to high-income countries. An unresolved hypothesis is that immunomodulation by parasitic infections such as helminths (prevalent in rural tropical settings) contributes to suppression of vaccine responses. Among 1-17-year-old Ugandan residents of rural Schistosoma mansoni (Sm)-endemic islands and proximate urban communities with lower helminth exposure, we assessed plasma antibody and whole blood assay cytokine responses to tetanus toxoid (TT) and purified protein derivative of Mycobacterium tuberculosis (PPD). These were taken to represent recall responses to tetanus and BCG vaccination in infancy. PPD-specific responses are additionally induced by tuberculous and non-tuberculous mycobacterial exposure. Urban-rural comparisons showed that PPD-specific IFN-γ and IL-13 and TT-specific IL-13 and IgG concentrations were lower in the rural setting, but that PPD-specific IgE concentrations were higher. Among rural participants, Sm infection was inversely associated with PPD-specific IFN-γ, while nematode infection was positively associated with PPD-specific IgG. Among urban participants, Sm infection was positively associated with PPD-specific responses but inversely associated with TT-specific responses, while nematode infection was inversely associated with TT-specific IgG and IgG4, but no associations were observed with PPD-specific responses. Despite these associations, for the urban-rural comparisons there were no notable changes in test statistics after adjusting for current helminth infections, suggesting that helminths were not the sole explanation for the urban-rural differences observed. Helminths likely work in concert with other environmental exposures and operational factors to influence vaccine response.Entities:
Keywords: Antibody; Cytokine; Purified protein derivative; Tetanus toxoid; Urban-rural; Vaccine
Mesh:
Substances:
Year: 2020 PMID: 32387542 PMCID: PMC7397513 DOI: 10.1016/j.parint.2020.102132
Source DB: PubMed Journal: Parasitol Int ISSN: 1383-5769 Impact factor: 2.230
Fig. 1Study flowchart.
Participants' characteristics.
| Characteristic | Urban | Rural | P value* |
|---|---|---|---|
| Male sex | 161/350 (46.0) | 500/966 (49.3) | 0.293 |
| Age | |||
| 1–4 | 116/350 (33.1) | 404/966 (40.5) | |
| 5–8 | 87/350 (24.9) | 299/966 (29.0) | |
| 9–12 | 64/350 (18.3) | 159/966 (17.2) | |
| 13–17 | 83/350 (23.7) | 104/966 (13.4) | |
| Place of birth | |||
| City | 17/345 (4.9) | 11/963 (1.5) | |
| Town | 302/345 (87.5) | 56/963 (5.6) | |
| Village | 26/345 (7.5) | 896/963 (92.9) | |
| Occupation | |||
| Student or child | 329/345 (95.4) | 937/963 (97.1) | |
| Unemployed or house wife | 3/345 (0.9) | 7/963 (0.9) | |
| Agricultural, fishing or lake related | 2/345 (0.6) | 13/963 (1.0) | |
| Professional or service providers (Shops, saloons, bars, restaurants, entertainment) | 11/345 (3.2) | 6/963 (0.9) | |
| Ever received immunisation | |||
| Any | 338/346 (97.7) | 619/662 (93.3) | |
| Bacille Calmette–Guérin (BCG) | 315/336 (93.8) | 586/619 (92.6) | 0.757 |
| Diphtheria, Pertussis and Tetanus (DPT) | 313/336 (93.2) | 571/619 (90.1) | 0.420 |
| Source of information about immunisation | |||
| Health card | 95/346 (27.5) | 217/623 (32.5) | |
| Self/parent/guardian reported | 242/346 (69.9) | 401/623 (66.0) | |
| No information | 9/346 (2.6) | 5/623 (1.6) | 0.509 |
| Presence of BCG scar | 263/350 (75.1) | 645/955 (66.3) | |
| Helminth infections | |||
| 27/282 (9.6) | 285/834 (35.4) | ||
| Uninfected | 255/282 (90.4) | 549/834 (64.7) | |
| Light | 13/282 (4.6) | 140/834 (17.1) | |
| Moderate | 11/282 (3.9) | 80/834 (10.2) | |
| Heavy | 3/282 (1.1) | 65/834 (8.1) | |
| 46/277 (16.6) | 417/830 (51.9) | ||
| Any nematode¥ | 18/276 (8.0) | 179/830 (23.3) | |
| 0/282 (0.0) | 8/834 (0.7) | 0.349 | |
| 9/276 (3.3) | 62/830 (7.2) | ||
| 7/282 (2.5) | 112/834 (11.9) | ||
| 3/277 (1.1) | 20/830 (2.2) | 0.289 | |
| Any anthelminthic treatment in last year | 263/346 (76.0) | 800/961 (81.4) | |
| 0/334 (0.0) | 64/960 (7.2) | ||
| Malaria treatment in the last year | 147/344 (42.7) | 710/963 (72.9) | |
| HIV infection | 3/337 (0.9) | 12/513 (2.8) |
KK: Kato-Katz; PCR: Polymerase Chain Reaction; denominators for each characteristic represent the number of participants that responded to the respective questions or for whom a sample was available for laboratory analysis; *P values obtained from Pearson chi square test, values in bold are significant at 0.05; infection with any of A. lumbricoides, N. americanus, T. trichiura, or S. stercoralis; Percentages adjusted for survey design.
Purified protein derivative- and tetanus toxoid-specific responses: urban-rural comparisons.
| Vaccine antigen | Cytokine / Antibody | Geometric meanβ | Unadjusted | Adjusted for age, sex, BCG scar and place of birth | |||
|---|---|---|---|---|---|---|---|
| GMR (95% CI)# | P value§ | GMR (95% CI)# | P value§ | ||||
| Urban* | Rural | ||||||
| PPD | IFN-γ | 831.3 | 164.0 | 0.20 (0.13, 0.30) | 0.22 (0.14, 0.35) | ||
| IL-5 | 13.8 | 14.2 | 1.02 (0.67, 1.57) | 0.917 | 1.04 (0.43, 2.52) | 0.932 | |
| IL-13 | 34.9 | 8.4 | 0.24 (0.17, 0.35) | 0.22 (0.12, 0.40) | |||
| IL-10 | 37.8 | 28.1 | 0.74 (0.52, 1.06) | 0.098 | 0.55 (0.27, 1.10) | 0.086 | |
| IgG | 19,700.9 | 22,549.0 | 1.15 (1.01, 1.30) | 1.07 (0.94, 1.21) | 0.295 | ||
| IgE | 92.7 | 115.2 | 1.24 (0.09, 1.72) | 0.182 | 1.56 (1.07, 2.29) | ||
| IgG4 | 92.0 | 94.7 | 1.03 (1.00, 1.06) | 1.02 (0.96, 1.09) | 0.501 | ||
| TT | IFN-γ | 14.6 | 7.3 | 0.50 (0.24, 1.08) | 0.077 | 0.69 (0.27, 1.78) | 0.435 |
| IL-5 | 5.5 | 3.7 | 0.66 (0.36, 1.23) | 0.185 | 0.64 (0.34, 1.19) | 0.152 | |
| IL-13 | 11.2 | 3.0 | 0.27 (0.13, 0.52) | 0.36 (0.19, 0.68) | |||
| IL-10 | 5.3 | 5.8 | 1.07 (0.78, 1.47) | 0.652 | 0.96 (0.63, 1.48) | 0.859 | |
| IgG | 51,760.4 | 47,418.3 | 0.92 (0.84, 0.99) | 0.83 (0.74, 0.93) | |||
| IgE | 504.7 | 679.0 | 1.35 (1.01, 1.79) | 1.12 (0.53, 2.39) | 0.758 | ||
| IgG4 | 14,006.7 | 12,289.7 | 0.88 (0.76, 1.02) | 0.080 | 0.82 (0.64, 1.05) | 0.109 | |
*reference category is urban setting; Cytokine concentrations in pg/ml, antibody concentrations in ng/ml; Geometric mean ratios (GMR) and 95% CI adjusted for survey design; P values in bold are significant at 0.05; PPD: purified protein derivative; TT: tetanus toxoid; 95% CI: 95% confidence interval.
Fig. 2Age-stratified mean concentrations of PPD- and TT-specific cytokines and antibodies. A: Mean purified protein derivative (PPD)-specific antibody and cytokine responses stratified by age (in years) in the rural and urban surveys. B: Mean tetanus toxoid (TT)-specific antibody and cytokine responses stratified by age (in years) in the rural and urban surveys. Plotted results are from all participants, irrespective of Schistosoma mansoni infection status.
*Mann-Whitney test was used to assess differences in cytokine responses between 1 and 4-year olds and 5–8-year olds. P < .001 for all four TT-specific cytokines.
Association between current S. mansoni infection status and PPD- and tetanus toxoid-specific responses in the rural and urban setting.
| Vaccine antigen | Cytokine / Antibody | Geometric meanβ | Unadjusted | Adjusted for age, sex, BCG scar and place of birth | |||
|---|---|---|---|---|---|---|---|
| GMR (95% CI)# | P value§ | GMR (95% CI)# | P value§ | ||||
| A: Rural survey | |||||||
| PPD | IFN-γ | 180.9 | 143.1 | 0.79 (0.57, 1.07) | 0.123 | 0.70 (0.50, 0.99) | |
| IL-5 | 16.7 | 13.2 | 0.79 (0.48, 1.31) | 0.350 | 0.72 (0.42, 1.25) | 0.232 | |
| IL-13 | 10.0 | 7.6 | 0.76 (0.51, 1.12) | 0.161 | 0.75 (0.48, 1.19) | 0.211 | |
| IL-10 | 28.7 | 26.8 | 0.93 (0.61, 1.44) | 0.752 | 0.98 (0.65, 1.47) | 0.901 | |
| IgG | 20,696.3 | 24,511.4 | 1.18 (1.08, 1.30) | 1.04 (0.96, 1.13) | 0.315 | ||
| IgE | 97.8 | 128.8 | 1.32 (0.89, 1.96) | 0.166 | 1.40 (0.90, 2.18) | 0.131 | |
| IgG4 | 92.8 | 95.1 | 1.03 (0.99, 1.07) | 0.197 | 1.03 (0.98, 1.07) | 0.286 | |
| TT | IFN-γ | 7.2 | 6.6 | 0.92 (0.47, 1.79) | 0.804 | 0.94 (0.51, 1.71) | 0.821 |
| IL-5 | 4.1 | 3.1 | 0.76 (0.49, 1.20) | 0.238 | 0.83 (0.49, 1.40) | 0.472 | |
| IL-13 | 3.3 | 2.6 | 0.80 (0.54, 1.17) | 0.241 | 0.86 (0.57, 1.30) | 0.465 | |
| IL-10 | 5.9 | 5.1 | 0.86 (0.61, 1.22) | 0.407 | 0.98 (0.67, 1.43) | 0.916 | |
| IgG | 49,742.5 | 44,871.3 | 0.90 (0.82, 0.99) | 0.95 (0.86, 1.04) | 0.272 | ||
| IgE | 702.1 | 637.5 | 0.91 (0.58, 1.42) | 0.662 | 0.96 (0.60, 1.55) | 0.873 | |
| IgG4 | 11,763.9 | 12,533.5 | 1.07 (0.91, 1.25) | 0.431 | 1.17 (0.97, 1.41) | 0.095 | |
| B: Urban survey | |||||||
| PPD | IFN-γ | 787.0 | 915.8 | 1.16 (0.78, 1.73) | 0.430 | 1.02 (0.72, 1.43) | 0.916 |
| IL-5 | 13.4 | 14.4 | 1.08 (0.44, 2.64) | 0.861 | 1.21 (0.63, 2.34) | 0.545 | |
| IL-13 | 31.0 | 49.5 | 1.60 (0.94, 2.71) | 0.080 | 1.75 (1.19, 2.56) | ||
| IL-10 | 38.6 | 38.3 | 0.99 (0.62, 1.59) | 0.977 | 0.88 (0.55, 1.41) | 0.574 | |
| IgG | 18,794.9 | 24,511.1 | 1.30 (1.14, 1.49) | 1.14 (1.00, 1.31) | 0.054 | ||
| IgE | 93.7 | 107.3 | 1.15 (0.66, 2.00) | 0.615 | 1.20 (0.70, 2.06) | 0.497 | |
| IgG4 | 91.3 | 101.3 | 1.11 (0.99, 1.24) | 0.065 | 1.12 (1.00, 1.26) | ||
| TT | IFN-γ | 15.9 | 4.6 | 0.29 (0.11, 0.76) | 0.35 (0.13, 0.91) | ||
| IL-5 | 5.5 | 2.7 | 0.49 (0.23, 1.06) | 0.068 | 0.79 (0.37, 1.69) | 0.519 | |
| IL-13 | 11.9 | 4.0 | 0.33 (0.16, 0.71) | 0.53 (0.24, 1.20) | 0.117 | ||
| IL-10 | 5.4 | 4.6 | 0.85 (0.55, 1.32) | 0.451 | 0.98 (0.62, 1.53) | 0.907 | |
| IgG | 51,109.5 | 41,861.6 | 0.82 (0.71, 0.95) | 0.92 (0.79, 1.07) | 0.257 | ||
| IgE | 493.3 | 353.4 | 0.72 (0.20, 2.52) | 0.586 | 0.73 (0.23, 2.26) | 0.560 | |
| IgG4 | 13,176.7 | 12,644.4 | 0.96 (0.67, 1.38) | 0.814 | 1.13 (0.84, 1.52) | 0.399 | |
Sm+: positive Kato-Katz and/or PCR test for diagnosis of current infection with Schistosoma mansoni;Sm-: negative Kato-Katz and PCR test for diagnosis of current infection with Schistosoma mansoni; *reference category is Schistosoma mansoni uninfected group; Cytokine concentrations in pg/ml, antibody concentrations in ng/ml; Geometric mean ratios (GMR) and 95% CI adjusted for survey design; P values in bold are significant at 0.05; PPD: purified protein derivative; TT: tetanus toxoid; 95% CI: 95% confidence interval.
Association between current infection with any nematode and PPD- and tetanus toxoid-specific responses in the rural and urban setting.
| Vaccine antigen | Cytokine / Antibody | Geometric meanβ | Unadjusted | Adjusted for age, sex, BCG scar and place of birth | |||
|---|---|---|---|---|---|---|---|
| GMR (95% CI)# | P value§ | GMR (95% CI)# | P value§ | ||||
| A: Rural survey | |||||||
| PPD | IFN-γ | 159.3 | 149.5 | 0.94 (0.61, 1.44) | 0.761 | 0.81 (0.46, 1.42) | 0.445 |
| IL-5 | 14.5 | 14.8 | 1.02 (0.74, 1.41) | 0.897 | 0.92 (0.63, 1.36) | 0.661 | |
| IL-13 | 8.5 | 8.4 | 0.98 (0.75, 1.28) | 0.887 | 0.90 (0.61, 1.34) | 0.597 | |
| IL-10 | 27.5 | 27.4 | 1.00 (0.78, 1.27) | 0.967 | 1.00 (0.76, 1.32) | 0.998 | |
| IgG | 21,838.4 | 26,564.9 | 1.22 (1.12, 1.32) | 1.10 (1.02, 1.19) | |||
| IgE | 112.3 | 119.2 | 1.06 (0.77, 1.47) | 0.709 | 1.08 (0.83, 1.41) | 0.558 | |
| IgG4 | 92.9 | 98.8 | 1.06 (1.00, 1.13) | 1.06 (1.00, 1.13) | 0.065 | ||
| TT | IFN-γ | 6.8 | 6.9 | 1.00(0.53, 1.89) | 0.994 | 0.93 (0.57, 1.53) | 0.777 |
| IL-5 | 3.8 | 2.6 | 0.70 (0.48, 1.02) | 0.065 | 0.73 (0.53, 1.02) | 0.064 | |
| IL-13 | 3.0 | 2.4 | 0.81(0.60, 1.11) | 0.178 | 0.83 (0.62, 1.12) | 0.209 | |
| IL-10 | 5.7 | 4.5 | 0.78 (0.59, 1.03) | 0.076 | 0.88 (0.70, 1.09) | 0.242 | |
| IgG | 47,359.2 | 45,680.6 | 0.97 (0.87, 1.07) | 0.480 | 0.98 (0.89, 1.08) | 0.716 | |
| IgE | 655.6 | 725.4 | 1.11 (0.73, 1.68) | 0.622 | 1.18 (0.80, 1.76) | 0.389 | |
| IgG4 | 12,001.9 | 12,923.3 | 1.08 (0.82, 1.41) | 0.577 | 1.11 (0.86, 1.43) | 0.405 | |
| B: Urban survey | |||||||
| PPD | IFN-γ | 790.4 | 1163.6 | 1.47 (0.96, 2.26) | 0.074 | 1.39 (0.92, 2.10) | 0.109 |
| IL-5 | 13.3 | 17.8 | 1.34 (0.36, 5.01) | 0.649 | 1.52 (0.46, 5.03) | 0.467 | |
| IL-13 | 33.6 | 37.2 | 1.11 (0.42, 2.89) | 0.826 | 1.21 (0.53, 2.78) | 0.637 | |
| IL-10 | 37.9 | 49.3 | 1.30 (0.90, 1.87) | 0.146 | 1.27 (0.84, 1.92) | 0.235 | |
| IgG | 19,452.7 | 22,875.3 | 1.18 (1.05, 1.32) | 1.05 (0.93, 1.19) | 0.409 | ||
| IgE | 97.1 | 79.0 | 0.81 (0.39, 1.72) | 0.572 | 0.78 (0.33, 1.86) | 0.561 | |
| IgG4 | 92.3 | 102.5 | 1.11 (0.88, 1.40) | 0.362 | 1.12 (0.89, 1.41) | 0.315 | |
| TT | IFN-γ | 13.1 | 7.4 | 0.56 (0.21, 1.53) | 0.240 | 0.68 (0.29, 1.57) | 0.337 |
| IL-5 | 4.8 | 4.4 | 0.92 (0.20, 4.30) | 0.913 | 1.25 (0.32, 4.88) | 0.735 | |
| IL-13 | 10.2 | 4.6 | 0.46 (0.09, 2.37) | 0.327 | 0.62 (0.14, 2.86) | 0.518 | |
| IL-10 | 5.2 | 4.5 | 0.86 (0.36, 2.08) | 0.722 | 0.95 (0.43, 2.10) | 0.888 | |
| IgG | 50,320.9 | 37,708.1 | 0.75 (0.64, 0.88) | 0.84 (0.71, 0.99) | |||
| IgE | 469.7 | 421.3 | 0.90 (0.16, 4.96) | 0.896 | 1.02 (0.19, 5.48) | 0.979 | |
| IgG4 | 13,485.6 | 8291.7 | 0.62 (0.50, 0.76) | 0.68 (0.53, 0.86) | |||
Nm+: positive Kato-Katz or PCR test for diagnosis of current infection with any of A. lumbricoides, N. americanus, T. trichiura, or S. stercoralis;Nm-: negative Kato-Katz and PCR test for diagnosis of current infection with any of A. lumbricoides, N. americanus, T. trichiura, or S. stercoralis; *reference category is uninfected group; Cytokine concentrations in pg/ml, antibody concentrations in ng/ml; Geometric mean ratios (GMR) and 95% CI adjusted for survey design; P values in bold are significant at 0.05; PPD: purified protein derivative; TT: tetanus toxoid; 95% CI: 95% confidence interval.
Do helminths underpin urban-rural differences in PPD- and tetanus toxoid-specific immune responses?
| Adjusted for age, sex, BCG scar and place of birth | Adjusted for age, sex, BCG scar, place of birth | Adjusted for age, sex, BCG | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaccine antigen | Cytokine / Antibody | Geometric meanβ | GMR (95% CI)# | P value§ | GMR (95% CI)# | P value§ | GMR (95% CI)# | P value§ | ||||
| PPD | IFN-γ | 831.3 | 164.0 | 0.22 (0.14, 0.35) | 0.24 (0.14, 0.41) | 0.22 (0.13, 0.37) | ||||||
| IL-5 | 13.8 | 14.2 | 1.04 (0.43, 2.52) | 0.932 | 1.26 (0.59, 2.68) | 0.542 | 1.16 (0.50, 2.70) | 0.727 | ||||
| IL-13 | 34.9 | 8.4 | 0.22 (0.12, 0.40) | 0.24 (0.13, 0.43) | 0.23 (0.12, 0.42) | |||||||
| IL-10 | 37.8 | 28.1 | 0.55 (0.27, 1.10) | 0.086 | 0.54 (0.26, 1.13) | 0.099 | 0.54 (0.24, 1.22) | 0.135 | ||||
| IgG | 19,700.9 | 22,549.0 | 1.07 (0.94, 1.21) | 0.295 | 1.05 (0.911, 1.20) | 0.523 | 1.05 (0.91, 1.21) | 0.470 | ||||
| IgE | 92.7 | 115.2 | 1.56 (1.07, 2.29) | 1.24 (0.81, 1.88) | 0.320 | 1.37 (0.89, 2.11) | 0.147 | |||||
| IgG4 | 92.0 | 94.7 | 1.02 (0.96, 1.09) | 0.501 | 0.99 (0.92, 1.06) | 0.673 | 0.99 (0.93, 1.06) | 0.836 | ||||
| TT | IFN-γ | 14.6 | 7.3 | 0.69 (0.27, 1.78) | 0.435 | 0.84 (0.34, 2.06) | 0.694 | 0.79 (0.31, 1.99) | 0.608 | |||
| IL-5 | 5.5 | 3.7 | 0.64 (0.34, 1.19) | 0.152 | 0.87 (0.49, 1.56) | 0.641 | 0.85 (0.49, 1.46) | 0.539 | ||||
| IL-13 | 11.2 | 3.0 | 0.36 (0.19, 0.68) | 0.48 (0.26, 0.90) | 0.46 (0.24, 0.87) | |||||||
| IL-10 | 5.3 | 5.8 | 0.96 (0.63, 1.48) | 0.859 | 0.96 (0.56, 1.66) | 0.881 | 0.97 (0.59, 1.61) | 0.918 | ||||
| IgG | 51,760.4 | 47,418.3 | 0.83 (0.74, 0.93) | 0.86 (0.75, 0.98) | 0.85 (0.74, 0.96) | |||||||
| IgE | 504.7 | 679.0 | 1.12 (0.53, 2.39) | 0.758 | 1.15 (0.49, 2.72) | 0.740 | 1.10 (0.44, 2.74) | 0.827 | ||||
| IgG4 | 14,006.7 | 12,289.7 | 0.82 (0.64, 1.05) | 0.109 | 0.82 (0.62, 1.08) | 0.148 | 0.86 (0.66, 1.11) | 0.239 | ||||
*reference category is urban setting; Cytokine concentrations in pg/ml, antibody concentrations in ng/ml; Geometric mean ratios (GMR) and 95% CI adjusted for survey design; Infection with any of A. lumbricoides, N. americanus, T. trichiura, or S. stercoralis; P values in bold are significant at 0.05; PPD: purified protein derivative; TT: tetanus toxoid; 95% CI: 95% confidence interval.